Novartis AGNVS reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10 but it was lower than the year-ago figure of $1.17. Revenues declined 1% to ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet the primary endpoint of sustained remission at week 52 for a new indication ...

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...

EAST HANOVER, N.J., July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx ® (secukinumab) in adults with newly diagnosed or ...

FRANKFURT, Feb 4 (Reuters) - Swiss drugmaker Novartis forecast a decline in 2026 operating profit in the low single-digit ...

Sales growth driven by continued strong performance from priority brands including Kisqali (+57% cc), Kesimpta (+36% cc), Pluvicto (+42% cc), Scemblix (+85% cc) and Cosentyx (+8% cc) Operating income ...

Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx ™ (secukinumab) in Europe to treat ankylosing spondylitis (AS) and ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

Novartis AG (NVS) reported Q4 2025 results, with net sales up 1% to $13.34B, missing estimates. Generic competition and ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance ...